Labcorp (LH) Projected to Post Quarterly Earnings on Tuesday

Labcorp (NYSE:LH) is anticipated to issue its Q4 2025 results before the market opens on Tuesday, February 17th. Analysts expect the company to announce earnings of $3.95 per share and revenue of $3.5597 billion for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 9:00 AM ET.

Labcorp Stock Performance

NYSE LH opened at $274.30 on Tuesday. Labcorp has a 1 year low of $209.38 and a 1 year high of $293.72. The firm has a market capitalization of $22.74 billion, a price-to-earnings ratio of 26.95, a P/E/G ratio of 1.75 and a beta of 1.03. The company has a current ratio of 1.55, a quick ratio of 1.35 and a debt-to-equity ratio of 0.59. The firm’s 50 day simple moving average is $261.92 and its 200 day simple moving average is $268.06.

Labcorp Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 12th. Stockholders of record on Friday, February 27th will be paid a $0.72 dividend. The ex-dividend date is Friday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. Labcorp’s dividend payout ratio (DPR) is presently 28.29%.

Hedge Funds Weigh In On Labcorp

Hedge funds have recently modified their holdings of the business. Brighton Jones LLC acquired a new stake in Labcorp in the fourth quarter valued at $991,000. Integrated Wealth Concepts LLC grew its position in shares of Labcorp by 7.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 2,427 shares of the medical research company’s stock valued at $565,000 after buying an additional 177 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Labcorp by 52.2% in the first quarter. Goldman Sachs Group Inc. now owns 353,843 shares of the medical research company’s stock valued at $82,353,000 after buying an additional 121,304 shares during the period. Arrowstreet Capital Limited Partnership bought a new position in shares of Labcorp during the second quarter worth about $5,873,000. Finally, First Trust Advisors LP raised its position in shares of Labcorp by 83.2% during the second quarter. First Trust Advisors LP now owns 86,046 shares of the medical research company’s stock worth $22,588,000 after acquiring an additional 39,087 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Truist Financial set a $320.00 price target on Labcorp in a report on Tuesday, October 14th. Robert W. Baird set a $313.00 target price on Labcorp in a research note on Wednesday, January 14th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. UBS Group decreased their price target on shares of Labcorp from $325.00 to $320.00 and set a “buy” rating on the stock in a report on Wednesday, October 29th. Finally, Weiss Ratings cut shares of Labcorp from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $300.75.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.